Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Ipca Laboratories among 5 stocks showing bullish RSI upswing
Five Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish momentum as their RSI crossed above 50, signaling potential upward price movement.
Epack Durable Ltd leads losers in 'A' group
Jubilant Foodworks Ltd, P I Industries Ltd, JK Lakshmi Cement Ltd and ERIS Lifesciences Ltd are among the other losers in the BSE's 'A' group today, 21 May 2026.
Eris Lifesciences among 5 stocks showing bullish RSI upswing
Five Nifty500 stocks featured in the RSI Trending Up scan on May 20 after gaining over 5%. The RSI moved above the 50 mark from lower levels, signalling improving momentum, strengthening price action, and potential short-term buying opportunities for traders tracking bullish technical setups and momentum-based market trends.
ERIS Lifesciences consolidated net profit rises 200.10% in the March 2026 quarter
Sales rise 7.07% to Rs 752.29 crore
Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth
The management of Eris Lifesciences said the phased rollout of the semaglutide portfolio, including pen-based products and obesity-focused SKUs, is expected to support growth momentum going ahead.
Eris Lifesciences spurts after Q4 PAT skyrockets 200% YoY to Rs 282 cr
Eris Lifesciences surged 8.57% to Rs 1,455.25 after the company's consolidated net profit zoomed 200.09% to Rs 281.61 crore in Q4 FY26 as against Rs 93.84 crore in Q4 FY25.
Eris Lifesciences shares decline nearly 6% after observations issued for Swiss facilities
11 out of the 12 analysts who have coverage on Eris Lifesciences have a "buy" rating on the stock, while the other one has a "hold" rating.
Eris Lifesciences says issues found at Swiss Parenterals units; impact likely minimal
Eris Lifesciences faces HALMED non compliance observations at Swiss Parenterals plants in Ahmedabad, plans GMP remediation with limited business impact expected. Shares of Eris Lifesciences Ltd ended marginally lower on Monday, April 20, by 0.91% at 1,432.40 on the NSE.
Neutral Eris Lifesciences; target of Rs 1520: Motilal Oswal
Motilal Oswal recommended Neutral rating on Eris Lifesciences with a target price of Rs 1520 in its research report dated February 14, 2026.
Buy Eris Lifesciences; target of Rs 1750: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Eris Lifesciences has recommended buy rating on the stock with a target price of Rs 1750 in its research report dated May 21, 2026.